Hyperion DeFi (NASDAQ:HYPD) Rating Increased to Hold at Zacks Research

Hyperion DeFi (NASDAQ:HYPD) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Thursday, Zacks reports.

A number of other equities research analysts have also issued reports on HYPD. Chardan Capital increased their price objective on shares of Hyperion DeFi from $7.30 to $8.45 and gave the company a “buy” rating in a report on Tuesday. Weiss Ratings raised shares of Hyperion DeFi from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, September 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $11.20 target price (up from $7.10) on shares of Hyperion DeFi in a research report on Thursday. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hyperion DeFi currently has a consensus rating of “Hold” and a consensus price target of $9.82.

Hyperion DeFi Stock Down 2.8%

HYPD stock opened at $3.49 on Thursday. The business’s 50-day moving average price is $2.97 and its 200-day moving average price is $3.29. The stock has a market cap of $54.23 million, a P/E ratio of -0.53 and a beta of 2.53. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.06. Hyperion DeFi has a twelve month low of $2.34 and a twelve month high of $15.00.

Hyperion DeFi (NASDAQ:HYPD) last posted its quarterly earnings results on Thursday, August 13th. The company reported $0.92 earnings per share for the quarter. Hyperion DeFi had a net margin of 416.56% and a negative return on equity of 11.62%. The business had revenue of $0.36 million during the quarter. On average, equities research analysts forecast that Hyperion DeFi will post 1.78 EPS for the current year.

Institutional Trading of Hyperion DeFi

Several hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD bought a new position in shares of Hyperion DeFi in the 4th quarter valued at about $73,000. State Street Corp purchased a new stake in Hyperion DeFi during the fourth quarter valued at approximately $92,000. Investment House LLC bought a new stake in shares of Hyperion DeFi in the 4th quarter valued at approximately $166,000. Geode Capital Management LLC purchased a new position in shares of Hyperion DeFi in the 4th quarter worth approximately $214,000. Finally, Focus Partners Advisor Solutions LLC bought a new position in shares of Hyperion DeFi during the 4th quarter valued at approximately $221,000. 25.84% of the stock is currently owned by hedge funds and other institutional investors.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.